World Biological Drugs Market 2013-2023 - a new market research report on companiesandmarkets.com
PR-Inside.com: 2014-03-14 12:05:03
The global biological drugs market will reach $178.4bn in 2017. In 2012, biologics represented 15% of the global pharmaceutical market, including seven of the top 10 products. Led by Humira and Remicade, monoclonal antibodies (mAbs) made up 41% of the 2012 market, fusion proteins 8%, and cellular and regenerative medicines 1%. The remainder of biologics revenues came from a range of protein therapeutics, with insulin and other recombinant hormones the most significant agents.
MAbs have the strongest R&D pipeline in the biologics market, the report indicates, with a range of next-generation technologies pushing mAb therapeutics into newer areas, including solid tumours, cardiovascular and neurological disorders. Diabetes represents a major growth opportunity for biologics, with new fusion proteins set to join Novo Nordisk´s Tresiba and other novel insulins on the market in the near future. Competition to develop the next wave of blockbusters in these areas and in the recombinant clotting proteins segment will offset revenue loss from waning erythropoietin and G-CSF products.
Biologics were one, two and three in the top ten drugs of 2012. People talk about the biotech revolution, but biotech is now one of the dominant, established powers in the pharmaceutical industry. All the main biotechs have either been acquired by Big Pharma or become major players in their own right.
The next big shift will come when biosimilars start to reach the market. The approval of LG Life Sciences´ biosimilar infliximab in South Korea is a sign of what´s to come. Once the EU´s new regulatory pathway for biosimilars has been established, we can expect the major markets to be inundated with biosimilars and biobetters. The entry barriers for bio-manufacturing and bio-processing have been greatly reduced, and even the suite of technologies that built the mAb market, from phage display to transgenic mice, are now off-patent and accessible to any company that´s interested. And biologics are going to become so prevalent that every major company will be interested in having a stake in that expanding market.
In terms of the multiple-blockbuster biologics, there hasn´t been a new one since Lucentis was approved in 2006. But the market continues to expand and broaden with a stream of new additions, and that will continue. There are also plenty of new technology platforms. From the approval of the Glybera gene therapy to the ADCs and other new antibody formats, to the new wave of stem cell therapeutics, there´s still a lot of exciting innovation in this market.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.